Accelerating Cell Line Development from DNA to Master Cell Bank
Modern cell line development (CLD) processes are tailored to the production of monoclonal antibodies, so it can be especially difficult to use common CLD platforms to manufacture other molecule types. As a result, it is common practice to find a contract development and manufacturing organization (CDMO) to develop your molecule and get it to the pre-clinical stage. However, knowing which CDMO partner best fits your needs is not always clear. When selecting a partner, it is important to select one that offers flexible platforms that can produce any molecule.
In this webinar, the AGC Biologics team discusses important factors to consider when selecting a CDMO partner, including workflows, timelines, and state-of-the-art technologies used in standard and adapted CLD processes. Learn about flexible platform options for the manufacturing of diverse molecule types and our collaborative services that help to shorten timelines. The team also presents four case studies that demonstrate our successes in custom CLD processes.
- Common CLD platforms may not be optimal for production of all molecules
- Diverse input molecules require flexible CLD technology and processes
- Flexible CLD platforms can shorten development timelines
- Examples from AGC Biologics, a full-service CDMO, specializing in custom CLD processes that support products from DNA transfection to master cell bank generation
Louise is a Cell Line Development scientist at AGC Biologics' Copenhagen facility, where she leads development lab teams in customer projects, as well as research and development-related activities for upstream development. Her experience and research have been focused on cell line engineering using CRISPR-based technologies in protein production and mammalian manufacturing platform and timeline optimization to help clients achieve effective timelines and product yields. She has over ten years of research and lab experience and holds a Ph.D. from the University of Copenhagen.